Frontlight ResearchEarly access
CompletedPhase 1
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
Key facts
- Who runs it
- Dr. Falk Pharma GmbH
- Where
- Austria, Finland, Germany, and Norway10 sites in 4 countriesChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 33 people enrolled
- Started
- 20 Jul 2023
- Ended
- 29 Nov 2024
- Type of study
- Interventional
- Record updated
- 15 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 15 September 2024